Evidence map›Paper›PMID 38449598›Full record

ArticleHeliyon2024

Comparison of post-resection survival between hepatocellular carcinoma patients in BCLC stage A or B who experience tumor rupture and patients in BCLC stage C who do not.

Su Jia-Yong, Wang Hong-Liang, Luo Ding-Wen, Chen Qing-Qing, Cai Yu-Tong, Tan Jun-Shao, Chen Mei, Tian Wei, Xie Rong-Wei, Ma Liang and 2 more

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Early Hemostatic Treatment Could Improve 30-Day Survival After Spontaneous Rupture of Hepatocellular Carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Su Jia-YongHepatobiliary Surgery Department, Guangxi Medical University Cancer Hospital, Nanning, China.
Wang Hong-LiangOrgan transplantation Department, 923rd Hospital of PLA Joint Logistic Support Force, Nanning, China.
Luo Ding-WenHepatobiliary Surgery Department, Guangxi Medical University Cancer Hospital, Nanning, China.
Chen Qing-QingGuangxi Crucial Laboratory of AIDS Prevention and Treatment & School of Public Health, Guangxi Medical University, Nanning, China.
Cai Yu-TongHepatobiliary Surgery Department, Guangxi Medical University Cancer Hospital, Nanning, China.
Tan Jun-ShaoNursing College of Guangxi Medical University, Nanning, China.
Chen MeiNursing College of Guangxi Medical University, Nanning, China.
Tian WeiHepatobiliary Surgery Department, Guangxi Medical University Cancer Hospital, Nanning, China.
Xie Rong-WeiHepatobiliary Surgery Department, Guangxi Medical University Cancer Hospital, Nanning, China.
Ma LiangHepatobiliary Surgery Department, Guangxi Medical University Cancer Hospital, Nanning, China.
Guo Ping-PingHepatobiliary Surgery Department, Guangxi Medical University Cancer Hospital, Nanning, China.
Zhong Jian-HongHepatobiliary Surgery Department, Guangxi Medical University Cancer Hospital, Nanning, China.
Guangxi Medical University · CN303 Hospital of People's Liberation Army · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aim: Spontaneous rupture of hepatocellular carcinoma (HCC) is a life-threatening complication, and patients who experience it are formally assigned to stage T4 in the TNM system, while many clinicians informally assign them to stage C in the more widely used Barcelona Clinic Liver Cancer (BCLC) system. The present study explored whether these re-staging practices are appropriate for HCC patients who suffer tumor rupture. Methods: We retrospectively reviewed the records of 1952 HCC patients who underwent hepatic resection at our hospital between January 2017 and June 2021. We compared recurrence-free and overall survival between 143 patients who had BCLC stage A or B disease at the time of spontaneous rupture and 449 patients who had BCLC stage C disease without rupture. Results: Overall survival rate was significantly higher among the 143 patients (1, 3, 5-year survival rate was 80.3%, 60.4%, 51.4%) with rupture than among the 449 (1, 3, 5-year survival rate was 69.5%, 41.5%, 32.4%) with BCLC stage C disease (hazard ratio 1.65, 95% confidence interval 1.29 to 2.12). The two groups had similar recurrence-free survival (hazard ratio 1.19, 95% confidence interval 0.92 to 1.53), but most patients with rupture were able to receive interventional and potentially curative treatments after recurrence, whereas most patients in BCLC stage C received interventional or supportive care. Similar results were obtained after propensity score matching. Conclusion: HCC patients who experience spontaneous rupture tumor while in BCLC stage A or B have better prognosis than patients in BCLC stage C without rupture. Our results suggest that HCC patients who suffer rupture in BCLC stage A or B should not be assigned to BCLC stage C.

Indexed as

BCLC stagePrognosisRuptured hepatocellular carcinoma

Identifiers

PMID38449598
PMCPMC10915404
OpenAlexW4392303081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.